VYLEESI (AUTOINJECTOR)

PeakPeptide

bremelanotide

NDASUBCUTANEOUSSOLUTION
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6

Clinical Trials (5)

NCT06565611Phase 2Active Not Recruiting

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

Started Aug 2024
108 enrolled
Obesity
NCT05709444Phase 2Completed

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Started Dec 2022
16 enrolled
Kidney Disease
NCT02338960Phase 3Completed

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Started Jan 2015
714 enrolled
Hypoactive Sexual Desire Disorder
NCT02333071Phase 3Completed

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Started Dec 2014
723 enrolled
Hypoactive Sexual Desire Disorder
NCT01382719Phase 2Completed

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Started Jun 2011
612 enrolled
Female Sexual Arousal DisorderHypoactive Sexual Desire Disorder

Loss of Exclusivity

LOE Date
Apr 29, 2041
184 months away
Patent Expiry
Apr 29, 2041

Patent Records (4)

Patent #ExpiryTypeUse Code
10286034
Nov 5, 2033
U-2568
9352013
Nov 5, 2033
U-2568
9700592
Nov 5, 2033
U-2568
11590209
Apr 29, 2041
U-3539
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers